S&P 500   3,850.19 (-0.04%)
DOW   31,155.62 (-0.11%)
QQQ   325.39 (+0.50%)
AAPL   136.11 (+3.09%)
MSFT   225.77 (+0.64%)
FB   272.10 (+1.73%)
GOOGL   1,901.81 (+1.16%)
AMZN   3,319.39 (+1.72%)
TSLA   845.61 (-0.57%)
NVDA   543.35 (+1.63%)
BABA   259.48 (-2.26%)
CGC   33.54 (-0.27%)
GE   11.15 (-2.11%)
MU   83.37 (-0.16%)
AMD   90.13 (+1.55%)
NIO   57.82 (+0.19%)
T   28.83 (-0.45%)
F   11.56 (+6.45%)
ACB   11.13 (-3.55%)
BA   207.29 (-1.97%)
DIS   171.71 (-1.11%)
NFLX   571.62 (-2.51%)
GILD   66.68 (-1.93%)
S&P 500   3,850.19 (-0.04%)
DOW   31,155.62 (-0.11%)
QQQ   325.39 (+0.50%)
AAPL   136.11 (+3.09%)
MSFT   225.77 (+0.64%)
FB   272.10 (+1.73%)
GOOGL   1,901.81 (+1.16%)
AMZN   3,319.39 (+1.72%)
TSLA   845.61 (-0.57%)
NVDA   543.35 (+1.63%)
BABA   259.48 (-2.26%)
CGC   33.54 (-0.27%)
GE   11.15 (-2.11%)
MU   83.37 (-0.16%)
AMD   90.13 (+1.55%)
NIO   57.82 (+0.19%)
T   28.83 (-0.45%)
F   11.56 (+6.45%)
ACB   11.13 (-3.55%)
BA   207.29 (-1.97%)
DIS   171.71 (-1.11%)
NFLX   571.62 (-2.51%)
GILD   66.68 (-1.93%)
S&P 500   3,850.19 (-0.04%)
DOW   31,155.62 (-0.11%)
QQQ   325.39 (+0.50%)
AAPL   136.11 (+3.09%)
MSFT   225.77 (+0.64%)
FB   272.10 (+1.73%)
GOOGL   1,901.81 (+1.16%)
AMZN   3,319.39 (+1.72%)
TSLA   845.61 (-0.57%)
NVDA   543.35 (+1.63%)
BABA   259.48 (-2.26%)
CGC   33.54 (-0.27%)
GE   11.15 (-2.11%)
MU   83.37 (-0.16%)
AMD   90.13 (+1.55%)
NIO   57.82 (+0.19%)
T   28.83 (-0.45%)
F   11.56 (+6.45%)
ACB   11.13 (-3.55%)
BA   207.29 (-1.97%)
DIS   171.71 (-1.11%)
NFLX   571.62 (-2.51%)
GILD   66.68 (-1.93%)
S&P 500   3,850.19 (-0.04%)
DOW   31,155.62 (-0.11%)
QQQ   325.39 (+0.50%)
AAPL   136.11 (+3.09%)
MSFT   225.77 (+0.64%)
FB   272.10 (+1.73%)
GOOGL   1,901.81 (+1.16%)
AMZN   3,319.39 (+1.72%)
TSLA   845.61 (-0.57%)
NVDA   543.35 (+1.63%)
BABA   259.48 (-2.26%)
CGC   33.54 (-0.27%)
GE   11.15 (-2.11%)
MU   83.37 (-0.16%)
AMD   90.13 (+1.55%)
NIO   57.82 (+0.19%)
T   28.83 (-0.45%)
F   11.56 (+6.45%)
ACB   11.13 (-3.55%)
BA   207.29 (-1.97%)
DIS   171.71 (-1.11%)
NFLX   571.62 (-2.51%)
GILD   66.68 (-1.93%)
Log in
OTCMKTS:CHOOF

Choom Stock Forecast, Price & News

$0.07
0.00 (0.00 %)
(As of 01/20/2021 12:00 AM ET)
Add
Compare
Today's Range
$0.06
Now: $0.07
$0.07
50-Day Range
$0.05
MA: $0.06
$0.07
52-Week Range
$0.05
Now: $0.07
$0.17
Volume960,219 shs
Average Volume867,527 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Choom Holdings Inc., through its subsidiaries, engages in the retail of cannabis. As of June 30, 2020, the company operates two medical and two coaching clinics under the name Concord Medical Centre; and 13 retail stores. The company was formerly known as Standard Graphite Corporation and changed its name to Choom Holdings Inc. in November 2017. Choom Holdings Inc. was incorporated in 2006 and is based in Vancouver, Canada.

MarketRank

Overall MarketRank

0.50 out of 5 stars

Medical Sector

1503rd out of 1,926 stocks

Drug Manufacturers - Specialty & Generic Industry

48th out of 61 stocks

Analyst Opinion: 0.0Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Drug Manufacturers - Specialty & Generic
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:CHOOF
CUSIPN/A
CIKN/A
Phone(604) 683-2509
EmployeesN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Next Earnings DateN/A
OptionableNot Optionable
$0.07
0.00 (0.00 %)
(As of 01/20/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive CHOOF News and Ratings via Email

Sign-up to receive the latest news and ratings for CHOOF and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Choom (OTCMKTS:CHOOF) Frequently Asked Questions

How has Choom's stock been impacted by COVID-19?

Choom's stock was trading at $0.0745 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, CHOOF stock has decreased by 11.7% and is now trading at $0.0658.
View which stocks have been most impacted by COVID-19
.

What stocks does MarketBeat like better than Choom?

Wall Street analysts have given Choom a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Choom wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Choom?

Choom saw a increase in short interest in the month of December. As of December 31st, there was short interest totaling 147,400 shares, an increase of 155.9% from the December 15th total of 57,600 shares. Based on an average trading volume of 1,149,900 shares, the short-interest ratio is currently 0.1 days.
View Choom's Short Interest
.

Who are some of Choom's key competitors?

Who are Choom's key executives?

Choom's management team includes the following people:
  • Mr. Christopher Bogart, Pres & Director (Age 49)
  • Ms. Terese J. Gieselman, CFO & Sec. (Age 57)
  • Mr. Corey Gillon, CEO & Director
  • Mr. Patrick G. Downey, Founder (Age 60)
  • Mr. Chris Gagan, Sr. VP of Branding & Marketing
  • Mr. Aussie Jiwani, Director of Sales
  • Ms. Daphne Kao, VP of People & Culture
  • Dr. Lamar Hanna, Sr. VP of Retail

What is Choom's stock symbol?

Choom trades on the OTCMKTS under the ticker symbol "CHOOF."

How do I buy shares of Choom?

Shares of CHOOF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Choom's stock price today?

One share of CHOOF stock can currently be purchased for approximately $0.07.

What is Choom's official website?

The official website for Choom is www.standardgraphite.com.

How can I contact Choom?

The company can be reached via phone at (604) 683-2509.

This page was last updated on 1/21/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.